targacept

Hapoalim is out with its research report today on Targacept (NASDAQ: TRGT) following TRGT's analyst day. In a note to clients, Hapoalim writes, "Targacept hosted an Analyst Day yesterday, highlighting inflammation and Parkinson's disease as its next focus areas. In addition to the new therapeutic...

Deutsche Bank has initiated coverage on Targacept (NASDAQ: TRGT) with a Buy rating and $32 price target. In a note to clients, Deutsche Bank writes, "Targacept is developing drugs to treat depression, ADHD, and other neurological conditions. Its lead compound, TC-5214, is in phase 3 for treatment-...

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that: J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt...